Expertise in
27
conditions

Dr. Sujana Movva

Oncology
Rockefeller Outpatient Pavilion
160 E 53rd St, 
New York, NY 
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
Rockefeller Outpatient Pavilion
160 E 53rd St, 
New York, NY 

Overview

Sujana Movva is an Oncologist practicing medicine in New York, New York.

Dr. Movva is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Pancreaticoduodenectomy, and Splenectomy.

She is actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 6 clinical trials. Dr. Movva is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Rockefeller Outpatient Pavilion
160 E 53rd St, New York, NY 10022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drugs: Ribociclib, Everolimus
Study Phase: Phase 2
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: Surufatinib+Tislelizumab
Study Phase: Phase 1/Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

54 Total Publications

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.
Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 27, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (1.2 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (0.1 miles away)
929-343-3624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Tap is an Oncologist practicing medicine in New York, New York. Dr. Tap is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization. Dr. Tap is currently accepting new patients.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (0.1 miles away)
646-583-3648
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.

Frequently Asked Questions about Dr. Sujana Movva

How do I make an appointment with Dr. Sujana Movva?

You can book an appointment with Dr. Sujana Movva by calling their office at 929-343-3631. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sujana Movva a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sujana Movva is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sujana Movva specialize in?

While Dr. Sujana Movva is a Oncology, they have specific expertise in Adult Soft Tissue Sarcoma, Liposarcoma, and Undifferentiated Pleomorphic Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Sujana Movva participate in research or clinical trials?

Yes. Dr. Sujana Movva has published 54 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Dr. Sujana Movva's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sujana Movva accept my insurance?

Dr. Sujana Movva accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 929-343-3631 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Movva's expertise for a condition
ConditionClose
View All 19 Distinguished Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile